Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4 Pt 1
|
pubmed:dateCreated |
1993-12-3
|
pubmed:abstractText |
N6-cyclopentyladenosine (CPA), a selective adenosine A1 receptor agonist, in a concentration range of 10(-9) to 10(-7) M, produced a significant decrease in erythropoietin (EPO) levels in a human hepatocellular carcinoma (Hep G2) cell culture (medium levels of EPO, 91.81 +/- 1.61 and 94.36 +/- 0.97% of control, respectively) after 24 h incubation in a hypoxic atmosphere. CPA, at a concentration of 10(-9) M, also produced a significant decrease in Hep G2 cell levels of adenosine 3',5'-cyclic monophosphate (cAMP; 78.13 +/- 3.89% of control) after 2 h incubation. CPA (10(-9) M) also significantly inhibited forskolin-stimulated increases in EPO production and cAMP accumulation in Hep G2 cells. On the other hand, 2-[p-(2-carboxyethyl)phenethyl-amino]-5'-N-ethylcarboxamidoadenosine (CGS-21680), a selective adenosine A2-receptor agonist, produced no significant change in EPO production in a dose range of 10(-10) to 10(-6) M but increased cAMP accumulation at 10(-6) M. A1-receptor binding assays using N6-[3H]cyclohexyladenosine revealed a single type of adenosine receptor binding site on Hep G2 cell membranes with a dissociation constant of 71.4 nM and a binding capacity of 1,530 fmol/mg protein. These results indicate that Hep G2 cells contain high-affinity adenosine A1 receptors that are linked to decreased cAMP accumulation and EPO production.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adenosine,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclic AMP,
http://linkedlifedata.com/resource/pubmed/chemical/Erythropoietin,
http://linkedlifedata.com/resource/pubmed/chemical/Forskolin,
http://linkedlifedata.com/resource/pubmed/chemical/N(6)-cyclohexyladenosine,
http://linkedlifedata.com/resource/pubmed/chemical/N(6)-cyclopentyladenosine,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Purinergic P1
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0002-9513
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
265
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
C934-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8238318-Adenosine,
pubmed-meshheading:8238318-Carcinoma, Hepatocellular,
pubmed-meshheading:8238318-Cyclic AMP,
pubmed-meshheading:8238318-Erythropoietin,
pubmed-meshheading:8238318-Forskolin,
pubmed-meshheading:8238318-Humans,
pubmed-meshheading:8238318-Liver Neoplasms,
pubmed-meshheading:8238318-Receptors, Purinergic P1,
pubmed-meshheading:8238318-Tumor Cells, Cultured
|
pubmed:year |
1993
|
pubmed:articleTitle |
Adenosine A1 receptors and erythropoietin production.
|
pubmed:affiliation |
Department of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana 70112.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|